Progress and Challenges with Inhibition of K-Ras GTPase in Cancer

Dear Colleagues,

For decades, activated by mutations K-Ras GTPase has been an important cancer drug target, but still, there are no approved inhibitors for clinical use. The reasons are multiple, including alternative ways of post-translational processing, the lack of deep pockets for high affinity inhibitor binding, and compensatory pathways for downstream signalling. Now, several K-Ras inhibitors are undergoing clinical trials and more inhibitors are under consideration for testing in cancer patients. These developments suggest that many hurdles with inhibiting K-Ras in cancer have been finally overcome. Significant progress with the development of novel inhibitors of K-Ras urges the research community to address different questions, such as “Which oncogenic mutants of K-Ras can be targeted by the available inhibitors?”, “What types of K-Ras-driven cancer can be most effectively treated with these compounds?, or “Are there any potential mechanisms of resistance to K-Ras inhibition and how this resistance can be avoided?”. Answers to these questions will likely shape future research to optimize the current K-Ras inhibitors and to develop innovative strategies for enhanced blocking of K-Ras signalling in cancer. This Special Issue will focus on analysis of the available approaches to K-Ras inhibition, identification of the patient populations that will benefit the most from the current anti-K-Ras compounds, understanding potential resistance to K-Ras inhibition, and outlining plans to address emerging limitations of K-Ras inhibitors.

Prof. Vadim Gaponenko
Prof. Gary A. Piazza
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• K-Ras
• Oncogenic mutations
• K-Ras signaling
• K-Ras-driven cancer
• inhibitors
• mechanisms of resistance